Subscribe To
Why bridgebio pharma was a healthy stock today
A well-respected financial services company initiated coverage on the biotech. It flagged it with its equivalent of a buy recommendation....
October 24, 2023, 7:57 pm
bridgebio pharma announces new england journal of medicine publication of positive encaleret proof-of-concept phase 2b results in patients with autosomal dominant hypocalcemia type 1 (adh1)
– In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing h...
October 10, 2023, 11:30 am
bridgebio: bets acoramidis as the pfizer spoiler
bridgebio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, ...
September 25, 2023, 11:05 pm
bridgebio pharma announces positive feedback from the u.s. fda and eu ema on the regulatory path for a pivotal phase 3 trial of infigratinib in children with achondroplasia
– bridgebio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and...
September 6, 2023, 11:30 am
bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...
August 27, 2023, 10:15 am
bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- bridgebio Pharma, Inc. (Nasdaq: BBIO) (“...
August 24, 2023, 4:01 pm
Wall street thinks bridgebio pharma could rise over 40% -- but will it?
This young biotech might soon commercialize a new medicine. Analysts see bridgebio's shares headed upwa...
August 9, 2023, 10:07 am
Why shares of bridgebio pharma skyrocketed this week
bridgebio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well ...
July 21, 2023, 10:44 am
bridgebio pharma surges on positive heart drug news
bridgebio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on deve...
July 18, 2023, 10:25 am
bridgebio pharma (bbio) moves 75.9% higher: will this strength last?
bridgebio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than ...
July 18, 2023, 6:04 am
bridgebio pharma: positive attr-cm treatment data leads to other 2023 catalysts
Primary endpoint met in bridgebio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for ...
July 17, 2023, 6:42 pm
bridgebio pharma stock soars on heart disease drug study results
bridgebio Pharma Inc shares surged 69% to $30.78 in late-morning trading on Monday after the commercial...
July 17, 2023, 11:33 am
: bridgebio’s stock rockets 66% on news of positive results from late-stage trial of attr-cm treatment
bridgebio Pharma Inc.’s stock BBIO rocketed 66% in premarket trade Monday, after the company announce...
July 17, 2023, 11:32 am
Pharma stock soars on heart disease drug trial
bridgebio Pharma Inc (NASDAQ:BBIO) stock is one of the best stocks on Wall Street today, after the phar...
July 17, 2023, 10:52 am
Why is bridgebio (bbio) stock up 63% today?
bridgebio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from...
July 17, 2023, 10:04 am
bridgebio's stock rockets 66% on news of positive results from late-stage trial of attr-cm treatment
bridgebio Pharma Inc.'s stock BBIO, +5.26% rocketed 66% in premarket trade Monday, after the company an...
July 17, 2023, 7:32 am